组蛋白去甲基化酶与肿瘤发生

组蛋白甲基化修饰是一个可逆的动态的调节过程。甲基化和/或去甲基化状态与表观遗传、转录调控和维持基因组完整性等密切相关。组蛋白甲基化状态异常会直接或间接影响各种生理和病理过程。已知组蛋白去甲基化酶包括赖氨酸特异性去甲基化酶（LSD）家族和含JmjC结构域的JMJD家族。研究发现,两者与肿瘤的发生均有着密切的关系。本文总结了组蛋白去甲基化酶在组蛋白甲基化修饰及肿瘤研究方面的最新进展,为组蛋白修饰的功能及肿瘤诊断、治疗、预后监测等研究提供新思路。在胃癌、乳腺癌、结肠癌等常见肿瘤中,组蛋白去甲基化酶可改变组蛋白的甲基化水平或者直接作用于癌基因,也可调节microRNA或转录因子等,促进或抑制肿瘤的发生发展与影响肿瘤的预后。     

组蛋白去甲基化酶研究进展

组蛋白甲基化是一种重要的表观遗传修饰方式,2004年组蛋白去甲基化酶的发现使人们认识到组蛋白的甲基化也是一个可逆的修饰过程,并由此掀起了人们对组蛋白去甲基化研究的热潮。该文主要从近年来研究人员在组蛋白去甲基化酶的鉴定、组蛋白去甲基化酶的功能研究等方面取得的进展进行阐述,并就该方面的研究进行展望。     

组蛋白甲基化研究进展

组蛋白甲基化是表观遗传修饰方式中的一种,参与异染色质形成、基因印记、X染色体失活和基因转录调控.组蛋白甲基化过程的异常参与多种肿瘤的发生.既往认为组蛋白甲基化是稳定的表观遗传标记,而组蛋白去甲基化酶的发现对这一观点提出了挑战,也为进一步深入研究组蛋白修饰提供新的途径.     

组蛋白去甲基化酶LSD1及其生物学功能

赖氨酸特异性组蛋白去甲基化酶1(Lysine specific demethylase 1, LSD1) 的发现, 表明组蛋白的甲基化修饰是一个动态可调节的过程。结构分析显示, LSD1 是一个黄素腺嘌呤二核苷酸(Flavin adenine dinulcleotide, FAD) 依赖性胺氧化酶, 它能够特异性脱去单甲基化和二甲基化组蛋白H3第4位赖氨酸(H3K4) 和H3K9 位点上的甲基基团。功能研究显示, LSD1 定位于细胞核内, 调控着基因转录的激活和抑制, 被誉为细胞深处的基因“开关”, 在胚胎发育和肿瘤发生过程中起着重要的作用。文章主要综述了LSD1 的结构、作用机制及其调控作用研究的新进展。     

赖氨酸特异性组蛋白去甲基化酶1作用机制及其生物学功能的研究进展

与其他化学修饰,如乙酰化、磷酸化、泛素化等相似,组蛋白赖氨酸甲基化是一个可以逆转的组蛋白修饰,是一个动态调节的过程。赖氨酸特异性组蛋白去甲基化酶1（lysine specific demethylase 1,LSD1）是一个黄素腺嘌呤二核苷酸（flavin adenine dinulcleotide,FAD）依赖性胺氧化酶,它能够特异性脱去H3K4和H3K9位点上的单甲基化和二甲基化的甲基基团。LSD1参与调控核受体介导的基因转录,并分别维持染色质的活性和非活性状态,被誉为细胞深处的基因＂开关＂。LSD1的功能失衡可引发多种重要生命现象的改变。主要综述LSD1的结构、作用机制及其在肿瘤发生、胚胎发育、体细胞重编程的调控、细胞分裂和造血等过程中生物学功能的研究新进展。     

组蛋白去甲基化酶1在干细胞增殖与分化中的调控作用

表观遗传学在干细胞的分化与成熟过程中扮演着重要的角色。其中发现组蛋白去甲基化酶1（LSD1）可以动态地调节组蛋白的甲基化状态,进而调控基因转录的激活和抑制以及X染色体失活等过程,LSD1在肿瘤干细胞、胚胎干细胞、神经干细胞及诱导多能干细胞中均有表达,并影响这些干细胞的增殖和分化过程。就LSD1在干细胞增殖与分化中的调控作用的研究进展进行综述。     

组蛋白去甲基化酶在发育和再生医学的研究

表观遗传学调控在器官发育以及再生医学中是重要的研究内容,而组蛋白的甲基化修饰属于表观遗传学调控机制之一并且成为近年来研究的热点内容。处于不同甲基化状态下的组蛋白,能影响多种分子对其的识别和结合,在转录起始、转录效率和转录后加工等多个层面调控相关基因的表达。而哺乳动物的器官发育与细胞重编程都与基因选择性表达密切相关,因此组蛋白甲基化状态在基因选择性表达中扮演着重要角色。本文概述了组蛋白去甲基化酶的分类以及组蛋白不同甲基化状态下对于基因的表达的调控,同时总结了组蛋白去甲基化酶在维持胚胎干细胞的多分化潜能和IPS细胞重编程效率方面的作用以及组蛋白去甲基化酶基因的缺失与相关器官发育的影响。最后探讨了组蛋白甲基化修饰酶在推动发育生物学与再生医学研究进展方面的潜能。     

组蛋白精氨酸甲基化修饰对基因转录的调控

总结了组蛋白精氨酸甲基化修饰体系的最新研究进展．组蛋白精氨酸甲基化修饰在基因转录调控中发挥着十分重要的作用,这类修饰由蛋白精氨酸甲基转移酶（PRMTs）介导,其中PRMT1和PRMT4的甲基化修饰与基因的转录激活作用相关,PRMT5和PRMT6的甲基化修饰则与基因的转录抑制作用相关．组蛋白精氨酸的甲基化是一个动态的可逆过程,催化组蛋白精氨酸的去甲基化是由“精氨酸去甲基化酶”介导的．     

组蛋白甲基化及其与肿瘤间的关系

组蛋白甲基化修饰是表观遗传学的重要研究领域之一,主要可分为精氨酸甲基化和赖氨酸甲基化两种。越来越多的证据表明组蛋白甲基化功能异常与肿瘤的发生发展密切相关,而且这种甲基化修饰过程是可逆的。对组蛋白甲基化的进一步研究,不仅有助于深入了解基因表达、调控、遗传等生理机制,而且对于肿瘤等重大疾病的诊断、防治和预后判断有重要意义。本文对组蛋白甲基转移酶、去甲基化酶及其与肿瘤发生发展的关系予以综述。     

组蛋白去甲基化酶JMJD家族的特点和功能

组蛋白甲基化修饰是造成表观遗传变化的原因之一,而去甲基化酶的发现证明甲基化修饰也是一个可逆过程.JMJD家族是一类重要的去甲基化酶,其催化活性需要Fe 2 和a-酮戊二酸的参与,可催化组蛋白H3多个位点赖氨酸的去甲基化修饰,从而调节了特定基因的表达. JMJD家族催化的去甲基化与精子发育、肿瘤发生及其他疾病发生存在密切关系,这些研究为许多生命问题的解决提供了新的思路,同时也为新药的开发提供了潜在的新靶点.     

MassSQUIRM: An assay for quantitative measurement of lysine demethylase activity

In eukaryotes, DNA is wrapped around proteins called histones and is condensed into chromatin. Post-translational modification of histones can result in changes in gene expression. One of the most well-studied histone modifications is the methylation of lysine 4 on histone H3 (H3K4). This residue can be mono-, di- or tri-methylated and these varying methylation states have been associated with different levels of gene expression. Understanding exactly what the purpose of these methylation states is, in terms of gene expression, has been a topic of much research in recent years. Enzymes that can add (methyltransferases) and remove (demethylases) these modifications are of particular interest. The first demethylase discovered, LSD1, is the most well-classified and has been implicated in contributing to human cancers and to DNA damage response pathways. Currently, there are limited methods for accurately studying the activity of demethylases in vitro or in vivo. In this work, we present MassSQUIRM (mass spectrometric quantitation using isotopic reductive methylation), a quantitative method for studying the activity of demethylases capable of removing mono- and di-methyl marks from lysine residues. We focus specifically on LSD1 due to its potential as a prime therapeutic target for human disease. This quantitative approach will enable better characterization of the activity of LSD1 and other chromatin modifying enzymes in vitro, in vivo or in response to inhibitors.Key words: LSD1, lysine demethylase, mass spectrometry, reductive methylation, monoamine oxidase (MAO) inhibitors     

MassSQUIRM

In eukaryotes, DNA is wrapped around proteins called histones and is condensed into chromatin. Post-translational modification of histones can result in changes in gene expression. One of the most well-studied histone modifications is the methylation of lysine 4 on histone H3 (H3K4). This residue can be mono-, di- or tri-methylated and these varying methylation states have been associated with different levels of gene expression. Understanding exactly what the purpose of these methylation states is, in terms of gene expression, has been a topic of much research in recent years. Enzymes that can add (methyltransferases) and remove (demethylases) these modifications are of particular interest. The first demethylase discovered, LSD1, is the most well-classified and has been implicated in contributing to human cancers and to DNA damage response pathways. Currently, there are limited methods for accurately studying the activity of demethylases in vitro or in vivo. In this work, we present MassSQUIRM (mass spectrometric quantitation using isotopic reductive methylation), a quantitative method for studying the activity of demethylases capable of removing mono- and di-methyl marks from lysine residues. We focus specifically on LSD1 due to its potential as a prime therapeutic target for human disease. This quantitative approach will enable better characterization of the activity of LSD1 and other chromatin modifying enzymes in vitro, in vivo or in response to inhibitors.     

Taking LSD 1 to a new high

Histone modifications mediate changes in gene expression by altering the underlying chromatin structure or by serving as a binding platform to recruit other proteins. One such modification, histone methylation, was thought to be irreversible until last year when Shi and co-workers broke new ground with their discovery of a lysine-specific histone demethylase (LSD 1). They showed that LSD 1, a nuclear amine oxidase homolog, is a bona fide histone H3 lysine 4 demethylase (Shi et al., 2004). Now, a new study from published in a recent issue of Molecular Cell, together with two studies recently published by and in Nature, reveal that LSD 1's specificity and activity is in fact regulated by associated protein cofactors.     

Crystal structure and mechanism of human lysine-specific demethylase-1

The reversible methylation of specific lysine residues in histone tails is crucial in epigenetic gene regulation. LSD1, the first known lysine-specific demethylase, selectively removes monomethyl and dimethyl, but not trimethyl modifications of Lys4 or Lys9 of histone-3. Here, we present the crystal structure of LSD1 at 2.9-A resolution. LSD1 forms a highly asymmetric, closely packed domain structure from which a long helical 'tower' domain protrudes. The active site cavity is spacious enough to accommodate several residues of the histone tail substrate, but does not appear capable of recognizing the different methylation states of the substrate lysine. This supports the hypothesis that trimethylated lysine is chemically rather than sterically discriminated. We present a biochemical analysis of LSD1 mutants that identifies crucial residues in the active site cavity and shows the importance of the SWIRM and tower domains for catalysis.     

The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines

Aberrant epigenetic silencing of tumor suppressor genes is a common feature observed during the transformation process of many cancers, including those of hematologic origin. Histone modifications, including acetylation, phosphorylation, and methylation, collaborate with DNA CpG island methylation to regulate gene expression. The dynamic process of histone methylation is the latest of these epigenetic modifications to be described, and the identification and characterization of LSD1 as a demethylase of lysine 4 of histone H3 (H3K4) has confirmed that both the enzyme and the modified histone play important roles as regulators of gene expression. LSD1 activity contributes to the suppression of gene expression by demethylating promoter-region mono- and dimethyl-H3K4 histone marks that are associated with active gene expression. As most post-translational modifications are reversible, the enzymes involved in the modification of histones have become targets for chemotherapeutic intervention. In this study, we examined the effects of the polyamine analogue LSD1 inhibitor 2d (1,15-bis{N ⁵-[3,3-(diphenyl)propyl]-N ¹-biguanido}-4,12-diazapentadecane) in human acute myeloid leukemia (AML) cell lines. In each line studied, 2d evoked cytotoxicity and inhibited LSD1 activity, as evidenced by increases in the global levels of mono- and di-methylated H3K4 proteins. Global increases in other chromatin modifications were also observed following exposure to 2d, suggesting a broad response to this compound with respect to chromatin regulation. On a gene-specific level, treatment with 2d resulted in the re-expression of e-cadherin, a tumor suppressor gene frequently silenced by epigenetic modification in AML. Quantitative chromatin immunoprecipitation analysis of the e-cadherin promoter further confirmed that this re-expression was concurrent with changes in both active and repressive histone marks that were consistent with LSD1 inhibition. As hematologic malignancies have demonstrated promising clinical responses to agents targeting epigenetic silencing, this polyamine analogue LSD1 inhibitor presents an exciting new avenue for the development of novel therapeutic agents for the treatment of AML.